Rakuten TV and Samsung TV Plus Reinforce Solid Partnership by Launching Over 166 Channels in 16 Markets
Rakuten TV strengthens its ongoing partnership with Samsung Electronics to expand its free content offering on the platform’s AVOD (Advertising-Video-on-Demand) service and launches over 20 of the platform's own and third-party channels on the Samsung TV Plus service across 16 European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005300/en/
TV Plus Interface (Graphic: Business Wire)
This launch opens new opportunities for advertisers to get in front of audiences across the new regions added to the Samsung TV Plus service, in addition to the possibility of reaching wider audiences through the broadening of channel line-up in territories already live.
During April and May Rakuten TV will roll out a total of 166 new channels in 16 markets through TV Plus.
With 20 premium channels, Rakuten TV will provide the full channel line-up exclusively for TV Plus as it expands its service into new territories. The roll-out started today with the launch of new channels in Denmark, Finland and Norway, followed by Belgium, Luxembourg, Portugal and Ireland planned for May.
Rakuten TV has also landed today at TV Plus in Sweden and the Netherlands with the launch of 7 premium channels.
In addition, alongside Rakuten TV's line-up already live on TV Plus in the UK, Spain, Germany, France, Italy, Austria and Switzerland, the Family channel became available in these markets on 14 April.
This launch will also broaden opportunities for advertisers, by extending reach to audiences across Europe. Samsung TV Plus sits alongside Rakuten Advertising's integrated portfolio, where publishers and advertisers can place ad-inventory across a variety of channels with the potential to reach more than 27M users across Europe. Through Rakuten TV channels available on TV Plus, brands will be able to run targeted campaigns to reach their potential new customers leveraging Rakuten Advertising’s powerful set of 1st party data and audience insights.
The enhanced line-up will provide the highest quality content at no cost. From top global channels, such as Africanews, Bloomberg TV, Bloomberg Quicktake, Euronews—the first live channel integrated into Rakuten TV's AVOD offer—Reuters and VENN, to a wide range of Rakuten TV's own themed channels curated by genres, from Action, Comedy, Drama, Spotlight, Family and Documentaries.
The new channels will be available on the TV Plus service in Samsung Smart TV devices from 2016 onwards in the UK, Spain, Germany, France, Italy, Austria, Switzerland; and in Samsung Smart TV devices from 2017 onwards in the rest of the markets.
Click here to download image: https://rak.box.com/s/5q7midm7sjgq2ldy86fnjdw3xe0bg3oo
About Rakuten TV
Rakuten TV is the first Video-On-Demand platform in Europe combining TVOD (Transactional video-on-demand), AVOD (Advertising video-on-demand) and SVOD (Subscription video-on-demand) services, providing users with a universe of content just one click away. While Rakuten TV's TVOD service provides a true cinematic experience with the latest new releases, the AVOD service offers a range of thematic channels for free, including Movies, Euronews, Kids TV, Viki, Documentaries and Rakuten Stories - a channel embodying Rakuten TV's original and exclusive content. On the subscription side, the platform provides the international SVOD service, Starzplay, as a premium content provider of movies and TV series.
Rakuten TV is available in 43 European territories and forms part of Rakuten Group, Inc. one of the worlds’ leading internet services companies, offering a wide variety of services for consumers and businesses, with a focus on e-commerce, fintech and digital content. Rakuten, headquartered in Japan, is also known for its partnership with FC Barcelona, the NBA, the Golden State Warriors, Davis Cup and Spartan Race.
www.rakuten.tv
About Rakuten Advertising
Rakuten Advertising provides advertising technology and consumer insights to the world’s leading brands and retailers. Working with agencies and brands around the world, Rakuten Advertising unites technology, client strategy and consumer insights to deliver advertising experiences that drive increased brand awareness and marketing performance. With access to Rakuten’s global audiences, media, content networks and consumer research, Rakuten Advertising creates the right conditions to reach new customers and sustain long-lasting loyalty. It is a division of Rakuten Inc. (4755: TOKYO), one of the world’s leading Internet service companies. The company is headquartered in San Mateo, CA, with offices in Australia, Singapore, Brazil, France, Germany, Ukraine, the United Kingdom and throughout the United States. Learn more at https://rakutenadvertising.com/
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry, and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
About TV Plus
Samsung TV Plus gives viewers instant access to top news, sports, entertainment, and more. It's 100% free and doesn't require any downloads, sign-up, credit cards, subscriptions or additional devices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005300/en/
Contact information
Rakuten TV
Fernanda Perabeles – PR & Communications Specialist - fernanda.perabeles@rakuten.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom